Full-Time
Director – Business Evolution Strategic Development
Updated on 9/3/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$160.5k - $305k/yr
Waukegan, IL, USA
Hybrid
Three in-office days per week required.
Bachelor's, MBA
 Business & Strategy (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- Bachelor’s degree required.
- MBA or other advanced degree in a relevant field preferred.
- Minimum of 6-8 years of progressively responsible experience in government affairs, public policy, market access, or business strategy, with a pharma company, healthcare consulting firm, government agency, or think tank.
- Strong business acumen with demonstrated experience in strategically and creatively shaping policy and business outcomes, with a keen understanding of what it takes to do so effectively.
- Exceptional communications, critical thinking and interpersonal skills, strong ability to influence without authority, the ability to speak and write persuasively and with clarity, strong organizational skills, flexibility, and adaptability to changing requirements, resourcefulness, strong attention to detail, a proven track record of being able to work drive towards deadlines and an ability to work collaboratively in a fluid organizational and external environment.
- Well-honed political sensitivities and the utmost integrity while having the executive presence and acumen necessary to deal effectively with and anticipate the needs of senior leaders and external stakeholders.
- Must be an individual who works well in a team environment and enjoys working in a collegial, collaborative and fun, yet highly demanding culture.
- Strategic Initiatives: Spearhead the development and execution of innovative and competitive strategies that integrate environment shaping with business readiness to navigate pharmaceutical price reform in the US today and in the future, collaborating tirelessly with cross-functional and external experts.
- Strategic Collaboration: Partner with critical stakeholders across Government Affairs, Market Access, Legal, Finance, and Corporate Affairs across geographies to ensure cohesive alignment towards enterprise goals. Drive strategies forward to achieve targeted objectives and milestones.
- Environmental Analysis and Horizon scanning: Together with key functions and external partners, monitor external political, regulatory, legislative, and market dynamics and develop impactful insight reports on evolving themes to help foster innovative solutions and strategic decision making.
- Business Value Evaluation: Identify opportunities to deliver actionable recommendations that enhance competitiveness and business impact. Support the building of compelling business cases to accelerate strategic solutions.
- Stakeholder Engagement: Develop effective presentations that enable strategic communications of issues, pivotal updates, and business cases to cross-functional leaders; maintain productive relationships with internal stakeholders, ensuring alignment and preparedness.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
- Apogee acquisition adds late-stage eczema and asthma assets, closing in Q3 2026.
- Rinvoq gained EU vitiligo and alopecia areata approvals in 2026, expanding peak sales.
What critics are saying
- Skyrizi and Rinvoq generated 42% of 2025 revenue, concentrating execution risk.
- Imbruvica sales fell 29.4% in Q2 2026, proving oncology weakness.
- A failed Apogee integration or weaker dermatology data would shrink 2026 earnings.
What makes AbbVie unique
- Skyrizi and Rinvoq drove $8.03 billion in Q2 2026 revenue.
- AbbVie owns a broad immunology pipeline, including Apogee's APG777 and APG273.
- AbbVie still pairs pharmaceuticals with Allergan aesthetics, including SKINVIVE and Botox.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.
AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.
AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion as it works to diversify beyond its core immunology portfolio. The pharmaceutical giant reported revenue of nearly $61.2 billion in FY 2025, up roughly 8.7% year-on-year, with Skyrizi and Rinvoq accounting for about 42% of sales. Eli Lilly achieved sharper growth, with revenue reaching nearly $65.2 billion in FY 2025, a 45% increase driven by GLP-1 drugs Mounjaro and Zepbound. These therapies represented roughly 56% of total revenue. Net income was approximately $20.6 billion. AbbVie's balance sheet shows a debt-to-equity ratio of negative 21x, whilst Eli Lilly's stands at roughly 1.6x. Free cash flow was nearly $17.8 billion for AbbVie and close to $9.0 billion for Eli Lilly.